Medical/Pharmaceuticals
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent ...
2022-01-06 20:30
4029
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
2022-01-06 19:00
2755
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...
2022-01-06 14:45
3646
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...
2022-01-06 08:30
7840
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to...
2022-01-06 01:00
2674
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
MINNEAPOLIS, Jan. 5, 2022 /PRNewswire/ -- Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. The purpose of the DeLIVER...
2022-01-05 22:00
1959
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., Chief Executive Of...
2022-01-05 20:45
3901
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
TOKYO, Jan. 4, 2022 /PRNewswire/ -- PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of ...
2022-01-05 09:00
2590
BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics
SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK
Biopharmaceuticals announcedtoday that they have forged a partnership to
research and develop new therapeutic compounds targeting microRNAs [1] (miRNA)
for a potential treatment of epilepsy.
2022-01-05 08:07
2556
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I tri...
2022-01-04 17:28
2556
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER
HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with concurrent chemoradiotherapy obtained approval from the Center for Dru...
2022-01-04 10:00
2977
Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, Jan. 3, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose has been administered in U.S. for its oral APL-1202 in combination ...
2022-01-04 08:06
2051
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr.Anthony Yeh to the position of Chief Strategy Officer and Head ofChina business development (BD), where he will lead corpor...
2022-01-03 18:00
2462
Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint
SHANGHAI, Jan. 1, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in treatment for cardiopulmonary disease, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study, being the first global completed pulmonary hyperten...
2022-01-01 20:30
3307
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences inJanuar...
2021-12-31 21:00
3383
China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally
HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...
2021-12-30 20:00
2955
Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology
SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...
2021-12-30 19:18
4551
iMEDISYNC UNVEILS WORLD'S FIRST INTEGRATED WIRELESS BRAIN EEG at CES 2022
SEOUL, South Korea, Dec. 29, 2021 /PRNewswire/ -- iMediSync, a leading AI-driven early detection and therapeutic platform for optimal brain health from Seoul, South Korea announced today that the company will showcase its comprehensive EEG solution (hardware + software + remote telehealth solution...
2021-12-30 00:00
3694
SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical
SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Appro...
2021-12-29 20:30
2962
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...
2021-12-28 22:00
2467
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 287 media titles]
2026-05-26 10:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8586
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8315
